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ABSTRACT
Objective The Surprise Question (SQ) is a 
prognostic screening tool used to identify 
patients with limited life expectancy. We 
assessed the SQ’s performance predicting 1- year 
mortality among patients in ambulatory heart 
failure (HF) clinics. We determined that the SQ’s 
performance changes according to sex and other 
demographic (age) and clinical characteristics, 
mainly left ventricular ejection fraction (LVEF) 
and the New York Heart Association (NYHA) 
functional classifications.
Methods We conducted a prospective 
cohort study in two HF clinics. To assess the 
performance of the SQ in predicting 1- year 
mortality, we calculated the sensitivity, specificity, 
positive and negative likelihood ratios, and 
the positive and negative predictive values. To 
illustrate if the results of the SQ changes the 
probability that a patient dies within 1 year, 
we created Fagan’s nomograms. We report 
the results from the overall sample and for 
subgroups according to sex, age, LVEF and NYHA 
functional class.
Results We observed that the SQ showed 
a sensitivity of 85% identifying ambulatory 
patients with HF who are in the last year of 
life. We determined that the SQ’s performance 
predicting 1- year mortality was similar among 
women and men. The SQ performed better for 
patients aged under 70 years, for patients with 
reduced or mildly reduced ejection fraction, and 
for patients NYHA class III/IV.
Conclusions We consider the tool an easy and 
fast first step to identify patients with HF who 
might benefit from an advance care planning 
discussion or a referral to palliative care due to 
limited life expectancy.
INTRODUCTION
People living with heart failure (HF), 
especially those in advanced stages of the 
disease, might present with uncontrolled 
symptoms such as shortness of breath, 
pain, sleep disorders and fatigue1 ; they 
also often suffer from comorbidities, such 
as depression and anxiety.2 Advance care 
planning (ACP) has proven to improve 
the quality of life and patient satisfaction 
with end- of- life care for patients with HF 
by promoting their autonomy concerning 
medical decisions.3 Identifying those with 
HF who are in the last year of their life is 
paramount to guide discussions and deter-
mine other strategies that are part of ACP, 
including possible referrals to specialised 
palliative care (PC).
The Surprise Question (SQ) is a prog-
nostic screening tool used to identify 
patients with limited life expectancy. The 
Key messages
What was already known?
 ► The performance of the Surprise Question 
(SQ) screening tool to predict 1- year 
mortality had been assessed among 
inpatient populations with heart failure 
(HF) and populations with HF in an 
emergency setting.
What are the new findings?
 ► The SQ’s performance predicting 1- year 
mortality in an ambulatory setting, a HF 
clinic, where patients with HF are more 
stable.
 ► The SQ’s performance predicting 1- 
year mortality for a population with HF 
according to patients’ sex, age, New York 
Heart Association functional class and left 
ventricular ejection fraction.
What is their significance?
Clinical:
 ► The SQ’s new psychometric profile allows 
for determining the appropriateness of its 
use in clinical practice at HF clinics and its 
predictive value for subgroup populations.
Research:
 ► This study contributes to filling gaps in 
the knowledge of the SQ’s performance in 
patients with HF in the ambulatory setting.
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SQ is a reflective question a physician or other health-
care providers ask themselves about a patient’s prog-
nosis: ‘would I be surprised if this patient dies within 
the next 12 months?’ An SQ is positive (+SQ) if the 
healthcare provider’s answer is ‘no, I would not be 
surprised’. There are also versions of the SQ within 
the context of 3 or 6 months. However, 1 year is the 
most common version.
The SQ’s performance has been evaluated for 
patients with both oncological4–7 and non- oncological 
diseases, including chronic kidney disease8 and chronic 
obstructive pulmonary disease.9 For patients with 
oncological diseases, the sensitivity of the 1- year SQ 
has varied from 58% to 85%.4–7 For patients with 
non- oncological diseases, the performance also varies 
even within the same disease.8–10 Despite the hetero-
geneity among performance measures, two systematic 
reviews suggest that, in general, the performance of 
the SQ predicting 1- year mortality is better for patients 
with oncological disease than for patients with non- 
oncological disease.10 11 Recently, the SQ’s performance 
was assessed for an inpatient population with HF12 and 
for a population with HF in an emergency setting.13 
The results were promising with a sensitivity of 85% 
for hospitalised patients and 79% for the emergency 
setting. However, the SQ’s performance in ambulatory 
settings, such as HF clinics where patients are more 
stable, is unknown. Furthermore, understanding the 
SQ’s performance for men and women is important 
to ensure equity in the delivery of ACP and PC. To 
our knowledge, the SQ’s performance for patients 
with HF, stratified according to the patient’s sex, has 
not yet been reported. Finally, given that HF clinic 
admission criteria and samples vary, it is important to 
understand the SQ’s performance according to other 
demographic and clinical characteristics to increase 
the generalisability of the results. Performance of the 
SQ is likely to differ across subgroups due to previous 
knowledge of the staff answering the question. For 
example, evidence has shown a trend of increasing 
mortality rates with increasing New York Heart Associ-
ation (NYHA) stage,14 increasing age15 and decreasing 
left ventricular ejection fraction (LVEF).16 17
Therefore, our objectives included (1) assessing the 
performance of the SQ predicting 1- year mortality 
among patients in ambulatory HF clinics, and (2) 
assessing whether performance changes according to 
sex, age, NYHA classification and LVEF category.
METHODS
This study was conducted and reported in accordance 
with the Strengthening the Reporting of Observational 
Studies in Epidemiology guidelines.18
Study design and setting
The prospective cohort included 174 ambulatory 
patients with HF who were recruited from two HF 
clinics in Medellín, Colombia between November 
2017 and November 2018. One- year vital status 
was determined by consulting the national mortality 
register in Colombia. Both clinics are part of tertiary 
care institutions that are referral centres for patients 
with cardiovascular disease. They offer comprehensive, 
multidisciplinary care that includes clinical follow- up 
by HF cardiologists, nursing education and telephone 
follow- up, cardiac rehabilitation, and a psychoeduca-
tional programme for patients and their families.
Participants
Patients were potentially eligible for the study if they 
were 18 years or older and existing patients at the HF 
clinic who had at least two prior consultations. Since 
the first two consultations provide the cardiologist an 
opportunity to optimise treatment if necessary and to 
get to know patients under optimal treatment circum-
stances according to clinical guidelines, we did not 
enrol newer HF clinic patients. We enrolled consecu-
tive eligible patients in the study. There were no exclu-
sion criteria.
Ethical aspects
We conducted the study in accordance with the ethical 
guidelines from the Declaration of Helsinki19; our 
study was approved by the research ethics commit-
tees of the institutions involved in the study. Informed 
consent was collected before participants enrolled in 
the study.
Data sources and measurements
We obtained sociodemographic characteristics (age, 
sex and marital status) from electronic medical 
records, along with values of the clinical variables: 
LVEF, number of hospitalisations in the last year, pres-
ence of cardiac implantable devices, NYHA functional 
class, comorbidities and current medications. Comor-
bidities included clinical depression, atrial fibrillation, 
type 2 diabetes mellitus, kidney disease, lung disease, 
coronary artery disease, obstructive sleep apnoea and 
hypothyroidism. Current medications included ACE 
inhibitors, beta- blockers and angiotensin receptor 
blockers.
When a patient met the eligibility requirements for 
study inclusion, the treating cardiologist answered the 
SQ for that patient. For patients that the cardiologist 
would not be surprised if they died within the next 
year, we coded as +SQ. For patients that the cardiol-
ogist would be surprised if they died within the next 
year, we coded as a negative SQ (−SQ).
Statistical methods
To describe the study sample, we used mean and SD 
to summarise continuous variables in case of normal 
distribution. In cases of skewed distribution, we used 
median and IQR. We assessed normality using Q–Q 
plots. We summarised categorical variables as frequen-
cies and percentages.
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To assess the SQ’s performance predicting 1- year 
mortality, we calculated the sensitivity and specificity, 
as well as the SQ’s positive (+LR) and negative (–LR) 
likelihood ratios and the positive (PPV) and negative 
(NPV) predictive values (online supplemental tables 1 
and 2). We interpreted the effect of the +LR on the like-
lihood of dying within 1 year based on the following 
classifications: no change if +LR=1; minimal increase 
if +LR between 1 and 2; small increase if +LR between 
2 and 5; moderate increase if +LR between 5 and 10; 
and substantial increase if +LR >10.20
To illustrate how the result of the SQ changes the 
probability that a patient dies within 1 year, we created 
Fagan’s nomograms.21 We also conducted a univari-
able regression to assess the relation between a +SQ 
and 1- year mortality.
We performed subgroup analysis, comparing 
groups according to sex, age, LVEF and NYHA func-
tional class. We created a categorical variable for 
median age (70 years) and another for LVEF (reduced 
LVEF ≤40%; mildly reduced LVEF 41%–49%; and 
preserved LVEF ≥50%).22
We performed all analyses with STATA V.15 (Stata 
Corp, College Station, Texas, USA).
RESULTS
Participants
Of the 184 patients who met the inclusion criteria 
and were potentially eligible, 178 consented to partic-
ipate in the study. Among these 178 participants, 4 
were excluded because their 1- year vital status was 
unknown (figure 1).
Table 1 shows baseline demographic and clinical 
characteristics of the study’s 174 participants. The 
sample had a median age of 70 (58–77), was predom-
inantly male, had reduced LVEF and NYHA class II. 
The prevalence of a +SQ was 48%. After 1 year, 20 
patients had died, giving an overall mortality rate of 
12%.
Performance of the SQ predicting 1-year mortality
After 1 year, mortality among those with a +SQ was 
21%; mortality among those with a –SQ was 3% 
(p<0.001). Participants with a +SQ had 7.5 times 
higher odds of death at 1 year compared with those 
with a –SQ (OR 7.6, 95% CI 2.1 to 26.9).
The +LR is the probability that patients with +SQ 
will die within 1 year divided by the probability that 
patients with +SQ will be alive in 1 year.20 The +LR 
of the SQ was 1.98. The +SQ was nearly twice as 
likely for patients who died within 1 year than it 
was for patients who were alive in 1 year (figure 2). 
According to the classification of the +LR’s effect on 
the likelihood of dying within 1 year, it is a minor 
increase. The 1- year mortality rate for our study was 
12%. With the pretest probability of a patient dying 
within 1 year at 12% and a +LR of 1.98, the post- test 
probability of dying within 1 year is 20% (figure 3). 
A +SQ increased the probability that an ambulant 
patient with HF died within 1 year by 8 percentage 
points. The –LR was 0.26. The –SQ was nearly four 
times more likely assigned to participants who were 
alive in 1 year than it was for patients who died within 
1 year.
For our sample, the probability that the SQ correctly 
identified an individual who would die in the course 
of a year, the sensitivity was 85% (95% CI 69% to 
100%). The probability that the SQ would correctly 
identify an individual who would survive over a 
year, the specificity was 57% (95% CI 49% to 65%) 
(figure 2).
Figure 1 Flow chart of the patients included in the study.
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Subgroup analyses
We compared the SQ’s performance between women 
and men. Whereas other parameters were similar, the 
SQ’s sensitivity was 5 percentage points higher for 
women. With higher sensitivity, higher specificity and 
higher +LR, the SQ performed better for participants 
younger than 70 years (figure 2). Regarding LVEF’s 
classification, sensitivity, NPV and –LR were better for 
patients with reduced LVEF. Specificity, PPV and +LR 
were better for patients with mildly reduced LVEF. 
We observed the SQ’s worst performance for patients 
with preserved LVEF (figure 2). Among patients clas-
sified as NYHA III/IV, the SQ’s sensitivity was perfect 
(100%). This subgroup also had the best values of 
PPV and NPV. However, the SQ’s specificity was very 
low (31%) for patients at NYHA III/IV classification 
(figure 2).
Based on Fagan’s nomograms, we accounted for 
the clinical application of the +LR. We observed the 
biggest probability changes for patients with +SQ 
dying within 1 year for those aged under 70 years and 
for patients with mildly reduced LVEF. Having a +SQ 
increased the probability of dying within 1 year by 12 
and 14 percentage points, respectively (online supple-
mental figures 1–8). According to the +LR’s effect on 
the likelihood of dying within 1 year, the +LRs showed 
a small increase in the likelihood among women; those 
aged under 70 years and patients with mildly reduced 
LVEF. In the remaining subgroups, +LR showed a 
minimal increase in the likelihood of dying within 1 
year.
DISCUSSION
Key results
Our primary objective was to assess the SQ’s perfor-
mance predicting 1- year mortality among patients 
in ambulatory HF clinics. With a sensitivity of 85%, 
the SQ is a good tool to screen ambulatory HF clinic 
patients who might be in the last year of life. The SQ’s 
performance predicting 1- year mortality was similar 
among women and men. We also assessed the SQ’s 
performance according to sex and other demographic 
(age) and clinical characteristics. The SQ performed 
better for patients aged under 70 years; for those with 
reduced or mildly reduced ejection fraction; and for 
patients at NYHA III/IV classification. For the whole 
sample and the different subgroups, +LRs showed a 
minor or a small increase in the likelihood of a patient 
dying within 1 year, which is not good enough to 
consider that a patient has a life expectancy limited 
to 1 year.
Performance of the SQ by subgroup
The risk factors for developing HF differ between men 
and women, as do responses to treatment, symptom 
burden, and comorbidities due to both biological and 
cultural factors.23 Because of this, sex- specific results 
should be presented in research.24 Accounting for 
sex, determining survival rates for patients with HF 
has been inconclusive. Initially, the Framingham study 
showed better survival rates after HF diagnosis for 
women than for men.25 Later, other studies suggested 
worse survival rates for women,15 which was supported 
Table 1 Clinical and demographic characteristics of study 
participants
Patients included 
(n=174)
Age 70 (58–77)
Sex
  Women 78 (44.8%)
  Men 96 (55.2%)
Marital status
  Single 25 (14.4%)
  Married 91 (52.3%)
  Divorced/separated 11 (6.3%)
  Widow/widower 47 (27.0%)
Aetiology
  Ischaemic 62 (35.6%)
  Hypertensive 15 (8.6%)
  Idiopathic 69 (39.7%)
  Valvular 22 (12.6%)
  Toxic 6 (3.5%)
  LVEF (%) 32 (25–44)
Classification according to LVEF
  HFrEF 116 (66.7%)
  HFmrEF 28 (16.1%)
  HFpEF 30 (17.2%)
NYHA functional class
  I 57 (32.8%)
  II 82 (47.1%)
  III 34 (19.5%)
  IV 1 (0.6%)
Comorbidities
  Type 2 diabetes mellitus 55 (31.6%)
  Chronic kidney disease 84 (48.3%)
  Lung disease 25 (14.4%)
  Coronary artery disease 64 (36.8%)
  Atrial fibrillation 51 (29.3%
  Depression 18 (10.3%)
  Anxiety 7 (4.0%)
  Obstructive sleep apnoea 13 (7.5%)
  Obesity 20 (11.5%)
Hospitalisations in the last year 2 (1–2)
Implantable cardioverter defibrillator 42 (24.1%)
+SQ 83 (47.7%)
Mortality 20 (11.5%)
Medication
  Beta- blockers 164 (94.3%)
  ACE inhibitors 136 (78.2%)
  ARBs 130 (74.7%)
Data presented as number of patients (%) for categorical data or as median (IQR) for 
continuous data.
Those patients for whom the cardiologist would not be surprised if the patient died 
within the next year were coded as a +SQ.
ARBs, angiotensin receptor blockers; HFmrEF, heart failure with mildly reduced ejection 
fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with 
reduced ejection fraction; LVEF, left ventricular ejection fraction; SQ, Surprise Question.
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by women presenting with HF when they are older 
and have more comorbidities.23 However, the most 
recent evidence suggests that age- adjusted mortality is 
similar between sexes.26
Among the subgroups, the SQ’s best performance 
was for those aged under 70 years. The main differ-
ence between its performance for those older and 
younger than 70 years was specificity. An age over 70 
years likely contributes to a +SQ response from cardi-
ologists, leading to an increase in the proportion of 
false positives; thus, a reduction in specificity.
The best sensitivity was for the group of patients 
with reduced LVEF. With more evidence of effective 
therapies to reduce morbidity and mortality, this type 
of HF is the most studied and best understood.27 In 
addition, evidence has shown that for patients with 
LVEF regardless of age, the lower the LVEF, the higher 
the mortality.28 This might explain why the perfor-
mance of an intuitive prognostic tool is better for 
this type of HF. The worst performance was among 
patients with preserved LVEF. This type of HF is not 
well understood, and there is no evidence of pharma-
cological therapy that decreases mortality for patients 
with preserved LVEF.27 29 An intuitive prediction 
of mortality for this group of patients is especially 
complex because the relationship between LVEF and 
mortality is U shaped.16 28 Above certain LVEF values, 
age- adjusted mortality increases, which is comparable 
with patients with LVEF between 30% and 35%.16 28
As for NYHA classifications, all patients classified at 
NYHA III/IV who died had a +SQ, which led to a sensi-
tivity of 100%. However, for patients at NYHA III/IV 
functional class who survived 1 year, the majority also 
had a +SQ. Perhaps due to previous knowledge that 
mortality increases with increasing NYHA functional 
class, cardiologists are more likely to assign +SQ to 
patients with HF in more advanced stages of NYHA,14 
which is similar to what happens with older patients 
with HF.
Comparison with previous studies
Previously, the SQ’s performance predicting 1- year 
mortality had been evaluated for patients with HF 
in emergency13 and inpatient settings.12 In the emer-
gency department, the SQ has a sensitivity of 79% 
and a specificity of 57% when answered by emer-
gency physicians.13 For hospitalised patients, the SQ 
has a sensitivity of 85% and a specificity of 59% when 
answered by cardiologists.12 We found that the SQ’s 
sensitivity (85%) and specificity (57%) for outpa-
tient settings are equal to inpatient settings. Since 
the SQ’s sensitivity and specificity were the same 
for decompensated (inpatients) and stable patients 
(outpatients), it suggests that the SQ’s performance 
predicting 1- year mortality for patients with HF does 
not vary significantly. However, to compare the SQ’s 
performance across settings and its interpretation in 
clinical practice for individual patients, we would 
have to compare LRs. No studies assessing the SQ’s 
performance for populations with HF reported LRs. 
However, since LRs are calculated using sensitivity 
and specificity, we estimated them using other studies’ 
reported test sensitivities and specificities. The +LR 
and –LR were similar across settings and represent 
minimal increases in the likelihood of dying within 
1 year.
Figure 2 Performance of the SQ in predicting 1- year mortality among patients in ambulatory HF clinics. HFmrEF, heart failure with 
mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LR, likelihood ratio; NPV, negative predictive value; NYHA, New York Heart Association; PPV, positive predictive value; SQ, 
Surprise Question.
B
ern. P
rotected by copyright.
 on A
ugust 30, 2021 at U
niversitaetsbibliothek
http://spcare.bm
j.com
/
B
M
J S
upport P
alliat C
are: first published as 10.1136/bm
jspcare-2021-003143 on 17 A
ugust 2021. D
ow
nloaded from
 
 6 Gonzalez- Jaramillo V, et al. BMJ Supportive & Palliative Care 2021;0:1–8. doi:10.1136/bmjspcare-2021-003143
Original research
Interpretations for clinical practice
When there is high test sensitivity, fewer false negatives 
occur, which increases the chance that patients with 
HF in need of ACP or PC will receive these services. 
Since determining sensitivity was the main criterion 
to evaluate the SQ’s performance, we consider it is 
an acceptable prognostic screening tool for patients 
with HF. Yet, there remains a significant percentage 
of patients with HF within the last year of their life 
who might be left out (15% of the whole sample) and 
might benefit from ACP or PC. Both in this population 
and in the literature, the SQ predicts 1- year mortality 
well among patients with HF.12 13 However, there are 
several aspects of the tool that users should be aware 
of before applying it in clinical practice.
First, the SQ’s performance depends on the clinical 
expertise and experience of the staff using it, as well as 
their knowledge of the patient with HF. For example, 
Straw et al conducted a study that evaluated the SQ’s 
performance among an inpatient population with HF.12 
They showed that the SQ’s sensitivity decreased from 
85% when cardiologists used the tool to 75% when 
physicians in training used it; and from 90% when 
HF nurses used the SQ to 66% among non- specialist 
nurses. Second, screening strategies such as the SQ do 
not afford assessment of the complexity of patients’ 
needs or the level of training that professionals should 
have to address ACP discussions or provide PC .
Finally, a major limitation of this screening tool is that 
it potentially excludes patients who will survive longer 
than 1 year but still would benefit from ACP or PC. 
Even in scenarios when the SQ predicts mortality well, 
using life expectancy as the sole criterion for assessing 
the need for ACP or PC is limiting. We consider the 
SQ can be used as a screening tool to initiate ACP or 
refer to PC for patients with a life expectancy of less 
than 1 year. However, we also consider the parallel use 
of needs assessment tools for patients with life expec-
tancy of more than 1 year. For example, two recent 
systematic reviews of available tools to assess PC needs 
in patients with HF concluded that the Needs Assess-
ment Tool: Progressive Disease- Heart Failure (NAT: 
PD- HF) was the most appropriate tool to determine 
the unmet needs of patients with HF.30 31
The NAT: PD- HF offers an alternative solution to 
several previously discussed points: it is not based on 
survival prognosis or severity factors, but it compre-
hensively evaluates different spheres.
The NAT: PD- HF is made of questions to determine 
a patient’s physical and psychological symptoms, daily 
life activity limitations, spiritual concerns, financial or 
legal concerns, and health- related information needs. 
Although the NAT: PD- HF does not focus on PC 
needs or referrals for specialised PC services, it does 
assess patients’ unmet needs and matches those needs 
with appropriate services, including specialised PC and 
other services. Finally, the NAT: PD- HF assesses the 
patients’ and the caregivers’ needs, including the care-
giver’s ability to take care of the patient.32 However, 
in clinical situations where there is not enough time to 
gather answers to the NAT: PD- HF’s comprehensive 
question sets, there is enough time for the clinician to 
ask themselves the singular SQ, which is better than no 
needs screening at all.
Strengths and limitations of this study
The low proportion of patients classified as NYHA III/
IV might be a limit of the generalisability of our results. 
The risk of mortality increases with a higher NYHA 
classification.33 Among our population, 80% of the 
patients were classified as NYHA I or II. As expected, 
the mortality rate was low compared with what has 
been reported in other HF clinics where mortality is 
around 30%.12 13 However, as we conducted different 
subgroup analyses, including analysis according to 
NYHA functional class, we provide different analyses 
Figure 3 Fagan’s nomogram for the overall sample. Based on 
a pretest probability of dying within 1 year of 12%, the blue 
line shows a post- test probability of a patient with a positive 
Surprise Question (+SQ) dying within a year of 20% (95% CI 
17% to 25%) according to the positive likelihood ratio (+LR) of 
1.98. A +SQ increases the probability of a patient dying within 
1 year by 8 percentage points. The red line shows a post- test 
probability of a patient with a negative SQ (–SQ) dying within a 
year of 3% (95% CI 1% to 9%) according to the negative LR (–
LR) of 0.22. A –SQ decreases the probability of a patient dying 
within 1 year by 9 percentage points.
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that can be assessed according to each HF clinic 
population.
As most encounters between healthcare personnel 
and patients occur in ambulatory settings, a strength of 
this study is the contribution of the SQ’s psychometric 
profile for ambulatory patients with HF. In addition, 
when screening for limited life expectancy and the need 
to initiate ACP, since the outpatient population are more 
stable patients, ACP needs may be overlooked. The 
systematic use of a tool such as the SQ could help iden-
tify patients with HF eligible for end- of- life care without 
being limited by having ACP discussion or making deci-
sions within unstable medical contexts. Furthermore, 
to support better generalisation, this study provides 
substantial data regarding subcategories.
CONCLUSION
The SQ showed a good sensitivity predicting 1- year 
mortality for patients in ambulatory HF clinics. 
However, the likelihood of dying within 1 year 
increases little when having a +SQ. We suggest that the 
SQ can be used as a starting point to identify patients 
who might benefit from having an ACP discussion or a 
referral to PC due to limited life expectancy toward a 
patient’s end of life.
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